Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorUnal, Sezin
dc.contributor.authorBeken, Serdar
dc.contributor.authorInce, Deniz Anuk
dc.contributor.authorTuran, Ozden
dc.contributor.authorToygar, Ayse Korkmaz
dc.contributor.authorEcevit, Ayse
dc.contributor.authorAkcan, Abdullah Baris
dc.date.accessioned2025-10-06T06:30:10Z
dc.date.available2025-10-06T06:30:10Z
dc.date.issued2025
dc.identifier.issn2296-2360
dc.identifier.urihttps://doi.org/10.3389/fped.2025.1492716
dc.identifier.urihttp://hdl.handle.net/11446/5453
dc.description.abstractObjective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country. Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country. Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA <= 27(6/7): 98.6%, GA 28(0/7)-28(6/7): 89.0%, GA 29(0/7)-29(6/7): 75.3%, GA 30(0/7)-31(6/7): 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations. Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers in Pediatricsen_US
dc.identifier.doi10.3389/fped.2025.1492716
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcaffeineen_US
dc.subjectpremature neonateen_US
dc.subjectapnea of prematurityen_US
dc.subjectneonatal intensive care uniten_US
dc.subjectguidelineen_US
dc.titleCaffeine use in preterm neonates: national insights into Turkish NICU practicesen_US
dc.typearticleen_US
dc.departmentDBÜen_US
dc.identifier.volume13en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Unal, Sezin; Ince, Deniz Anuk; Turan, Ozden; Ecevit, Ayse] Baskent Univ, Fac Med, Dept Pediat, Div Neonatol, Ankara, Turkiye; [Beken, Serdar; Toygar, Ayse Korkmaz] Acibadem Mehmet Ali Aydinlar Univ, Dept Pediat, Div Neonatol, Fac Med,Atakent Hosp, Istanbul, Turkiye; [Akcan, Abdullah Baris] Adnan Menderes Univ, Fac Med, Dept Pediat, Div Neonatol, Aydin, Turkiye; [Akin, Mustafa Ali] On Dokuz Mayis Univ, Fac Med, Dept Pediat, Div Neonatol, Samsun, Turkiye; [Aktas, Selma] Acibadem Mehmet Ali Aydinlar Univ, Dept Pediat, Div Neonatol, Fac Med,Maslak Hosp, Istanbul, Turkiye; [Ciftdemir, Nukhet Aladag] Trakya Univ, Fac Med, Dept Pediat, Div Neonatol, Edirne, Turkiye; [Altuncu, Emel] Univ Hlth Sci, Kartal Dr Lutfi Kirdar City Hosp, Dept Pediat, Div Neonatol, Istanbul, Turkiye; [Altunhan, Huseyin] Necmettin Erbakan Univ, Fac Med, Dept Pediat, Div Neonatol, Konya, Turkiye; [Arcagok, Baran Cengiz] Acibadem Mehmet Ali Aydinlar Univ, Dept Pediat, Div Neonatol, Fac Med,Altunizade Hosp, Istanbul, Turkiye; [Armangil, Didem] Ozel Koru Ankara Hosp, Dept Psychol, Ankara, Turkiye; [Ozer, Esra Arun] Izmir Tinaztepe Univ, Fac Med, Dept Pediat, Fac Med, Izmir, Turkiye; [Aydin, Banu] Lokman Hekim Univ, Fac Med, Dept Endocrinol & Metab, Fac Med, Ankara, Ten_US
dc.authoridUnal, Irem/0000-0002-4214-928X
dc.authoridMoniri, Ariorad/0000-0002-5171-3532
dc.authoridGuney Varal, Ipek/0000-0002-3298-066X
dc.authoridUlu, Ersin/0000-0002-9798-2367
dc.identifier.pmid40083438en_US
dc.identifier.scopus2-s2.0-105008507361en_US
dc.identifier.wosWOS:001443933100001en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.scopusqualityQ2en_US
dc.snmzKA_WOS_20251006
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster